EXACT Sciences (NASDAQ:EXAS) is set to post its quarterly earnings results after the market closes on Tuesday, April 30th. Analysts expect EXACT Sciences to post earnings of ($0.64) per share for the quarter. EXACT Sciences has set its FY 2019 guidance at EPS.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Thursday, February 21st. The medical research company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.05. EXACT Sciences had a negative return on equity of 23.58% and a negative net margin of 38.54%. The business had revenue of $142.98 million during the quarter, compared to analysts’ expectations of $143.00 million. During the same period in the previous year, the firm posted ($0.18) earnings per share. The company’s revenue was up 63.6% on a year-over-year basis. On average, analysts expect EXACT Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ EXAS opened at $90.67 on Tuesday. EXACT Sciences has a twelve month low of $44.85 and a twelve month high of $99.52. The company has a quick ratio of 8.70, a current ratio of 8.99 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $11.49 billion, a PE ratio of -66.67 and a beta of 1.83.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. BidaskClub raised EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 16th. Finally, UBS Group lifted their price objective on EXACT Sciences from $109.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $100.18.
In related news, insider Kevin T. Conroy sold 9,169 shares of EXACT Sciences stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $95.07, for a total value of $871,696.83. Following the completion of the transaction, the insider now directly owns 923,961 shares in the company, valued at $87,840,972.27. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark Stenhouse sold 11,192 shares of EXACT Sciences stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $92.54, for a total value of $1,035,707.68. Following the completion of the transaction, the insider now owns 25,500 shares of the company’s stock, valued at $2,359,770. The disclosure for this sale can be found here. Over the last quarter, insiders sold 455,507 shares of company stock valued at $37,454,557. 3.20% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was first published by Highlight Press and is the property of of Highlight Press. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://highlightpress.com/2019/04/23/exact-sciences-exas-set-to-announce-quarterly-earnings-on-tuesday.html.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Read More: How Buying a Call Option Works
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.